BIOINVENT
BIOINVENT operates in Diversified Metals & Mining.
BIOINVENT (BIX) - Total Assets
Latest total assets as of September 2024: €1.09 Billion EUR
Based on the latest financial reports, BIOINVENT (BIX) holds total assets worth €1.09 Billion EUR as of September 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
BIOINVENT - Total Assets Trend (2016–2023)
This chart illustrates how BIOINVENT’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
BIOINVENT - Asset Composition Analysis
Current Asset Composition (December 2023)
BIOINVENT's total assets of €1.09 Billion consist of 80.9% current assets and 19.1% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 18.5% |
| Accounts Receivable | €11.93 Million | 0.9% |
| Inventory | €11.84 Million | 0.9% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2016–2023)
This chart illustrates how BIOINVENT's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BIOINVENT's current assets represent 80.9% of total assets in 2023, a decrease from 98.0% in 2016.
- Cash Position: Cash and equivalents constituted 18.5% of total assets in 2023, down from 81.8% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 0.9% of total assets.
BIOINVENT Competitors by Total Assets
Key competitors of BIOINVENT based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MANHATTAN ASSOC
BE:MHT
|
Germany | €698.14 Million |
|
TV BROADCAST
MU:TBCN
|
Germany | €6.25 Billion |
|
FIRST CITIZENS BC A
BE:FC6A
|
Germany | €220.57 Billion |
|
COSTCO WHSL
MU:CTO
|
Germany | €69.83 Billion |
|
GOLDMAN SACHS GROUP - Dusseldorf Stock Exchang
DU:GOS
|
Germany | €1.73 Trillion |
|
BURCKHARDT COMPRE N
MU:B5H
|
Germany | €1.07 Billion |
|
Public Service Company of New Mexico PFD 4.58%
PINK:PNMXO
|
USA | $886.19 Million |
|
2H0
F:2H0
|
Germany | €15.27 Million |
BIOINVENT - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - BIOINVENT generates 0.05x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - BIOINVENT is currently not profitable relative to its asset base.
BIOINVENT - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 13.29 | 19.41 | 4.09 |
| Quick Ratio | 13.16 | 19.20 | 3.98 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €934.92 Million | € 1.17 Billion | € 145.90 Million |
BIOINVENT - Advanced Valuation Insights
This section examines the relationship between BIOINVENT's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -18.2% |
| Total Assets | €1.40 Billion |
| Market Capitalization | $27.23K USD |
Valuation Analysis
Below Book Valuation: The market values BIOINVENT's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: BIOINVENT's assets decreased by 18.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for BIOINVENT (2016–2023)
The table below shows the annual total assets of BIOINVENT from 2016 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | €1.40 Billion | -18.22% |
| 2022-12-31 | €1.71 Billion | +18.30% |
| 2021-12-31 | €1.45 Billion | +80.32% |
| 2020-12-31 | €802.64 Million | +254.98% |
| 2019-12-31 | €226.11 Million | +87.80% |
| 2018-12-31 | €120.40 Million | -29.20% |
| 2017-12-31 | €170.05 Million | -38.46% |
| 2016-12-31 | €276.30 Million | -- |